A Study to Evaluate the Safety and Efficacy of BEAM-302 in Adult Patients With Alpha-1 Antitrypsin Deficiency (AATD) (NCT06389877)
A Phase 1/2 Dose-exploration and Dose-expansion Study to Evaluate the Safety and Efficacy of BEAM-302 in Adult Patients With Alpha-1 Antitrypsin Deficiency (AATD)-Associated Lung Disease and/or Liver Disease
🩺 Plain-English Summary (8th-Grade Level)
This is a Phase 1/2, multicenter, open-label, dose-exploration (Phase 1) and dose-expansion (Phase 2) study to evaluate the safety, tolerability, PK/PD, and efficacy of BEAM-302 in adult patients with AATD-associated lung disease and/or liver disease and to determine the optimal biological dose (OBD).
Who can join: Review the eligibility criteria below.
Location: Clinical Study Center — Birmingham, Alabama
Age range: 18 Years to 70 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (11 Sites)
- Clinical Study Center — Birmingham, Alabama
- Clinical Study Center — Boston, Massachusetts
- Clinical Study Center — Charleston, South Carolina
- Clinical Study Center — Adelaide,
- Clinical Study Center — Fitzroy,
- Clinical Study Center — Dublin,
- Clinical Study Center — Leiden,
- Clinical Study Center — Auckland,
- Clinical Study Center — Hamilton,
- Clinical Study Center — London,
- Clinical Study Center — Southampton,
📞 Contact the Study Coordinator
Phone: (857) 327-8641
Email: clinicalinfo@beamtx.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Alpha 1-Antitrypsin Deficiency
- Study of BMN 349 Single Dose in PiZZ and PiMZ/MASH Adult Participants — San Diego, California
- Long-term, Open-label Study of SAR447537 (INBRX-101) in Adults With Alpha-1 Antitrypsin Deficiency Emphysema — Birmingham, Alabama
- Alpha-1 Antitrypsin Disease Cohort: Longitudinal Biomarker Study of Disease — Birmingham, Alabama
- Alpha-1 Research Registry — Coral Gables, Florida
- Gene Therapy for Alpha 1- Antitrypsin Deficiency — New York, New York
Explore by condition: All Alpha 1-Antitrypsin Deficiency clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.